Clinical Trials Logo

Agoraphobia clinical trials

View clinical trials related to Agoraphobia.

Filter by:

NCT ID: NCT00576719 Completed - Panic Disorder Clinical Trials

Effectiveness of Intensive Cognitive Behavioral Therapy in Treating Adolescent Panic Disorder and Agoraphobia

Start date: March 2005
Phase: Phase 2
Study type: Interventional

This study will evaluate the effectiveness of intensive cognitive behavioral therapy in treating adolescents with panic disorder with agoraphobia.

NCT ID: NCT00353470 Completed - Anxiety Disorders Clinical Trials

Comparison of Psychotherapy Programs to Treat Panic Disorder

Start date: September 2006
Phase: Phase 3
Study type: Interventional

This study will determine the relative effectiveness of three psychotherapies in treating people with a panic disorder.

NCT ID: NCT00202709 Completed - PTSD Clinical Trials

Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder?

Start date: May 2002
Phase: N/A
Study type: Interventional

The purpose of this study is to find out if Thought Field Therapy has effect on certain anxiety disorders; agoraphobia, social phobia, and post traumatic stress disorder (PTSD).

NCT ID: NCT00182533 Terminated - Clinical trials for Major Depressive Disorder

Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders

Start date: July 2002
Phase: Phase 4
Study type: Interventional

Selective serotonin reuptake inhibitors (SSRIs) including sertraline have been found to be effective in the treatment of generalized social phobia (GSP). However, virtually all of the current treatment studies with medicines, including the SSRIs, have excluded patients with social phobia who have other co-occurring conditions. In fact, 80% of individuals suffering with primary social phobia have at least one other anxiety. This study will evaluate the safety and efficacy of sertraline in the treatment of generalized social phobia with co-occurring anxiety and mood disorders.

NCT ID: NCT00129610 Active, not recruiting - Panic Disorder Clinical Trials

Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia

Start date: January 2004
Phase: N/A
Study type: Interventional

The study aims at comparing virtual reality therapy (VRT) with a usual cognitive behavior therapy (CBT) program for agoraphobia. A waiting list represents the control condition. The investigators' purpose is to test a pure VRT compared with a pure CBT, as previous works suggest that the combination of the two methods are clinically effective. Patients receive a two-page information leaflet about the trial and sign an informed consent. After the first evaluation, they are randomized, in three centers (Lyon, Paris, Luxemburg), either to VRT (12 sessions) or CBT (12 sessions), or a waiting-list control condition for three months. After three months the waiting list is randomized to VRT or CBT. The follow-up is one year from entry into the active part of the trial.

NCT ID: NCT00004366 Completed - Panic Disorder Clinical Trials

Pilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular Dysfunction

Start date: August 1995
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Evaluate whether vestibular rehabilitation training is of value in reducing anxiety symptoms in patients with panic disorder with or without agoraphobia who have vestibular dysfunction as identified by clinical vestibular tests.

NCT ID: NCT00000368 Completed - Panic Disorder Clinical Trials

Treatment of Panic Disorder: Long Term Strategies

Start date: February 1999
Phase: Phase 3
Study type: Interventional

Cognitive behavior therapy (CBT) with or without medication has been used in the treatment of panic disorder (PD). The purpose of this study is 1) to determine whether nine months of maintenance cognitive-behavior therapy (CBT) significantly improves the likelihood of sustained improvement; and 2) to determine the acute acceptability and efficacy of medication therapy or continued CBT alone among patients who fail to respond sufficiently to an initial course of CBT alone. It has been found that patients with PD respond as well to CBT or medication alone as they do to a combination of the two. Since the combined treatments are expensive and CBT is associated with less risk of medical toxicity compared to medications, CBT alone will be used first. All patients will first receive CBT alone. If the patient responds to this therapy, the patient will be assigned randomly (like tossing a coin) to 1 of 2 groups. One group will continue to receive CBT (maintenance therapy) for 9 months. The other group of responders will not receive any further therapy. If a patient does not respond to CBT alone, he/she will be assigned randomly to 1 of 2 different groups. One group will receive paroxetine; the other will continue to receive CBT for a longer period. The response to treatment will be evaluated to see which regimen works best to treat PD. The study will last approximately 3 years. An individual may be eligible for this study if he/she has panic disorder with no more than mild agoraphobia (fear of being in public places) and is at least 18 years old.